Trials / Unknown
UnknownNCT04826406
A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
Camrelizumab Combined Apatinib in Patients With Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors: A Single-Arm, Open-Label, Phase II Study.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Hunan Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe and preliminary explore the efficacy and safety of the combination of Camrelizumab and Apatinib regimen in treating advanced hepatocellular carcinoma (HCC) participants who have progressed following prior Immune Checkpoint Inhibitors (ICIs) treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab combined Apatinib regimen | Camrelizumab 200mg iv every 2 weeks; Apatinib,250 mg/day. |
Timeline
- Start date
- 2021-02-03
- Primary completion
- 2022-03-02
- Completion
- 2023-08-30
- First posted
- 2021-04-01
- Last updated
- 2021-04-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04826406. Inclusion in this directory is not an endorsement.